Z-138 Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens, human
Cell Line Description	Z-138 is a human mature B-cell lymphoma cell line established from bone marrow collected from a 70-year-old male. The patient initially carried a diagnosis of chronic lymphocytic leukemia and later developed an aggressive lymphoblastoid terminal phase. The cells grow in suspension, carry the characteristic t(11;14)(q13;q32) abnormality, overexpress Cyclin D1, and display a defined mature B-cell immunophenotype. These features support research on mantle cell lymphoma biology, cell-cycle dysregulation, B-cell signaling, NF-κB pathways, apoptosis, drug response, and resistance.
Cell Type	Mature B-cell lymphoblast
Tissue	Bone marrow
Disease	Mantle cell lymphoma with blastoid transformation
Year Established	1990
Gender	Male
Age	70 years
Morphology	Lymphoblast-like
Growth Mode	Suspension
Culture Type	Continuous hematologic cancer cell line
Applications	1. Mantle cell lymphoma and blastoid-transformation research 2. t(11;14) and CCND1 dysregulation studies 3. Cyclin D1 function and cell-cycle analysis 4. B-cell receptor and mature B-cell signaling research 5. Classical and alternative NF-κB pathway studies 6. TRAF2-altered signaling research 7. Apoptosis and mitochondrial priming assays 8. Targeted therapy and combination screening 9. Drug-resistance and microenvironment studies 10. Cytokine production and response assays 11. Immunophenotyping and flow-cytometry method development 12. CRISPR, RNA interference, transcriptomic, and genomic studies
Characteristics
t(11;14) Abnormality	Most examined cells contain a derivative chromosome consistent with t(11;14)(q13;q32), the hallmark rearrangement linking the immunoglobulin heavy-chain region with the CCND1 locus
Cyclin D1 Status	Cyclin D1 is strongly overexpressed, consistent with the t(11;14)-positive mantle cell lymphoma background
Karyotype	Hyperdiploid male karyotype with a modal chromosome number of 49 and approximately 4% polyploid cells
B-Cell Immunophenotype	CD19-positive, CD20-positive, and CD23-positive; CD3-negative, CD5-negative, CD10-negative, and FMC7-negative
Immunoglobulin Gene Rearrangement	The immunoglobulin heavy-chain rearrangement matches the rearrangement detected in the patient-derived blast population, supporting continuity between the clinical specimen and the cultured line
Cytokine Production	Produces granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor; the original characterization found no proliferative response to either cytokine
TRAF2 Variant	TRAF2 c.341G>A, producing p.Trp114Ter
Mycoplasma Test	Negative
Culture Conditions and Handling
Culture Conditions	37°C in a humidified atmosphere containing 5% CO₂ in air
Culture Surface	Standard tissue-culture flasks; surface coating is not required for routine suspension propagation
Recommended Seeding Density	1 × 10⁵ to 2 × 10⁵ viable cells/mL after centrifugation and resuspension
Maximum Cell Density	Do not allow the culture to exceed 3 × 10⁶ cells/mL
Recommended Split Ratio	1:5 to 1:15
Medium Renewal	Add fresh complete medium every 2–3 days according to viable-cell density
Routine Maintenance	Cultures may be maintained by adding fresh medium as density increases. For a complete medium exchange, collect the suspension, centrifuge gently, remove spent medium, and resuspend the cells at 1 × 10⁵ to 2 × 10⁵ viable cells/mL.
Subculturing	1. Mix the suspension gently to obtain a representative sample. 2. Determine viable-cell density and examine morphology and debris. 3. Add fresh complete medium directly or collect the culture for complete medium replacement. 4. When replacing medium, centrifuge using a validated low-speed setting and remove the supernatant without disturbing the pellet. 5. Resuspend in pre-warmed complete medium at 1 × 10⁵ to 2 × 10⁵ viable cells/mL. 6. Transfer at a 1:5 to 1:15 ratio and return the culture to 37°C and 5% CO₂. 7. Monitor growth and feed before the density approaches 3 × 10⁶ cells/mL.
Recovery pH Control	Pre-equilibrate complete medium in the incubator for at least 15 minutes before adding thawed cells. Maintain the medium near pH 7.0-7.6 and minimize alkaline exposure during recovery.
Thawing	Thaw rapidly with gentle agitation in a 37°C water bath for approximately 2 minutes. Disinfect the vial exterior, transfer the contents into 9 mL complete medium, and continue under aseptic conditions.
Post-Thaw Centrifugation	Approximately 125 × g for 5-7 minutes before removing residual cryoprotectant
Cryopreservation Medium	Horse serum supplemented with 10% DMSO
Long-Term Storage	Below −130°C, preferably in the vapor phase of liquid nitrogen; −70°C storage is not suitable for continued preservation
Biosafety	Handle as human-derived research material under Biosafety Level 1 or the locally assigned equivalent. Apply site-specific risk assessment, aseptic technique, appropriate personal protective equipment, decontamination, and waste procedures.
Handling Notes	Record passage number, viable-cell density, split ratio, medium and horse-serum lot, feeding schedule, and time after seeding. Distinguish parental Z-138 from gene-edited, reporter-labeled, drug-selected, or otherwise adapted derivatives.

Cat.No.	Product Name	Price
CSC-RR0648	Luciferase Reporter Cell Line - Z-138	Inquiry
CSC-RO01668	OVAL Stable Cell Line - Z-138	Inquiry
CSC-RO01921	GFP/OVAL Stable Cell Line - Z-138	Inquiry
CSC-RO02174	Luc/OVAL Stable Cell Line - Z-138	Inquiry
CSC-RO02427	GFP/Luc/OVAL Stable Cell Line - Z-138	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry